Loading
JPXHealthcareBiotechnology
Latest quote
¥5,740
−¥50.00 · -0.86%
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.
Latest quote
¥5,740
−¥50.00 · -0.86%
Regular session · JST · Market data may be delayed.
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.
Day range
Current ¥5,740
52-week range
Current ¥5,740
Regular session · JST · Market data may be delayed.
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.
Day range
Current ¥5,740
52-week range
Current ¥5,740
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 28.55M JPY | 31.38M JPY | 63.04M JPY | 976.18M JPY | 642.49M JPY |
| Cost of goods sold | 242K JPY | 815K JPY | 32.43M JPY | 637.7M JPY | 443.69M JPY |
| Gross profit | 28.3M JPY | 31.38M JPY | 30.61M JPY | 338.49M JPY | 198.8M JPY |
| Research and development | 1.47B JPY | 1.09B JPY | 1.35B JPY | 947.49M JPY | 825.47M JPY |
| Selling, general, and administrative | 582M JPY | 1.72B JPY | 583.1M JPY | 574.64M JPY | 725.94M JPY |
| Operating expenses | 2.05B JPY | 1.71B JPY | 1.96B JPY | 1.54B JPY | 1.65B JPY |
| Interest income | 3.95M JPY | 2.15M JPY | 1.48M JPY | 587K JPY | 494K JPY |
| Interest expense | 5.23M JPY | 4.6M JPY | 3.6M JPY | 3.95M JPY | 4.17M JPY |
| Depreciation and amortization | 242K JPY | 815K JPY | 2.29M JPY | 914K JPY | 6.49M JPY |
| Operating income | −2.02B JPY | −1.68B JPY | −1.93B JPY | −1.2B JPY | −1.45B JPY |
| Net income | −2.06B JPY | −1.68B JPY | −1.94B JPY | −1.15B JPY | −1.62B JPY |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
